Your browser doesn't support javascript.
COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region's Experience.
Cocchio, Silvia; Zabeo, Federico; Tremolada, Giulia; Facchin, Giacomo; Venturato, Giovanni; Marcon, Thomas; Saia, Mario; Tonon, Michele; Mongillo, Michele; Da Re, Filippo; Russo, Francesca; Baldo, Vincenzo.
  • Cocchio S; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
  • Zabeo F; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
  • Tremolada G; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
  • Facchin G; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
  • Venturato G; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
  • Marcon T; Azienda Zero (Veneto Region), 35100 Padua, Italy.
  • Saia M; Azienda Zero (Veneto Region), 35100 Padua, Italy.
  • Tonon M; Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.
  • Mongillo M; Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.
  • Da Re F; Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.
  • Russo F; Regional Directorate of Prevention, Food Safety, Veterinary, Public Health-Veneto Region, 30123 Venice, Italy.
  • Baldo V; Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131 Padua, Italy.
Vaccines (Basel) ; 10(8)2022 Aug 20.
Article in English | MEDLINE | ID: covidwho-1997864
ABSTRACT
Even if most of the complications due to COVID-19 are observed in the elderly, in Italy the impact of COVID-19 among young people has not been negligible. Furthermore, their contribution to SARS-CoV-2 circulation is still unclear. These reasons have driven policy makers to involve subjects aged 5 to 17 years in the COVID-19 vaccination campaign. However, the trade-off of vaccinating this age-group should be further investigated, especially in view of the rise of new immunologically evasive variants of concern (VOCs). We used regional databases to retrospectively estimate vaccine effectiveness over time of each approved vaccination schedule among children (5-11) and adolescents (12-17). Our findings suggest that COVID-19 vaccines were highly effective and their protection levels lasted longer during a period of Delta variant predominance, whereas they offered just mild to moderate levels of protection-apparently affected by a rapid waning effect-in a period of Omicron variant predominance. Considering these results, it is plausible to evaluate a reformulation of possible future COVID-19 vaccination campaigns among underage subjects. However, effectiveness against serious complications due to COVID-19, as well as indirect benefits of underage vaccinations, should first be addressed. Furthermore, vaccine effectiveness should be kept monitored, as new VOCs may arise, but also new adapted vaccines may start being administered.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10081362

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10081362